



Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051
Date :

20 MAY 2019

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.

(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/ND/82761/2019/11/28044**

On the basis of the inspection carried out on **09/04/2019**, **10/04/2019** and **14/05/2019**, we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **ZIM LABORATORIES LIMITED**
Address : **B-21/22, MIDC AREA, KALMESHWAR,
NAGPUR 441501 MAHARASHTRA STATE,
INDIA**
2. Licence No. : **1224 In Form 25,
1036 In Form 28**

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
1	Capsules	Cephalosporins	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
2	Capsules	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
3	Granules	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
4	Oral Powders	Cephalosporins	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
5	Oral Powders	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
6	Pellets	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
12			

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 15 May 2022 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority:
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai - 400 051.
Maharashtra, INDIA
Tel: +91-22-26543384
Fax: +91-22-26543949
1MIZ1748276120191128044
ZIM LABORATORIES LIMITED - NEW-WHO-
GMP/CERT/ND/82761/2019/11/28044

Name of the Authorised person : **A. T. NIKHADE**

Signature :

Signature and Date : **Joint Commissioner (HQ) & Controlling
Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date: 16 May 2019**



16 MAY 2019

Explanatory notes

1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.
2. The certification number should be traceable within the regulatory authority issuing the certificate.
3. Where the regulatory authority issues a licence for the site, this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.
4. Table 1
List the dosage forms, starting materials, categories and activities. Examples are given below.

Example -1


Pharmaceutical Product (s) ¹	Category (ies)	Activity (ies)
Dosage form (s)		
Tablets	Cytotoxic	Packaging
	Hormone	Production, Packaging, Quality control.
Injectables	Penicillin	Repackaging & Labelling.
	Cefalosporin	Aseptic preparation, Packaging, Labelling.

Example - 2.

Pharmaceutical Product (s) ¹	Category (ies)	Activity (ies)
Starting material (s) ²		
Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available. International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.
6. The requirements for good practices the manufacture and quality control of drugs referred to in the certificate are those included in Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials. Good manufacturing practices and inspection. Volume 2, 1999. World Health Organization, Geneva and subsequent updates.





Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Date :

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.

(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/ND/82761/2019/11/28044**

On the basis of the inspection carried out on **09/04/2019 ,10/04/2019 and 14/05/2019** ,we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **ZIM LABORATORIES LIMITED**
Address : **B-21/22, MIDC AREA, KALMESHWAR,
NAGPUR 441501 MAHARASHTRA STATE,
INDIA**
2. Licence No. : **1224 In Form 25,
1036 In Form 28**


Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
7	Tablets	Cephalosporins	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
8	Tablets	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
12			

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 15 May 2022 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051
Maharashtra, INDIA.
Tel: +91-22-26592363/6
Fax: +91-22-26591959
1MIZ1748276120190516
ZIM LABORATORIES LIMITED - NEW-WHO-
GMP/CERT/ND/82761/2019/11/28044



Name of the Authorised person : **A. T. NIKHADE**

Signature :

Post and Date : **Joint Commissioner (HQ) & Controlling
Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:16 May 2019**

16 MAY 2019

Explanatory notes

1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.
2. The certification number should be traceable within the regulatory authority issuing the certificate.
3. Where the regulatory authority issues a licence for the site, this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.
4. Table 1
List the dosage forms, starting materials, categories and activities. Examples are given below.

Example -1

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Dosage form (s)		
Tablets	Cytotoxic	Packaging
	Hormone	Production, Packaging, Quality control.
Injectables	Penicillin	Repackaging & Labelling.
	Cefalosporin	Aseptic preparation, Packaging, Labelling.

Example - 2.

Pharmaceutical Product (s)1	Category (ies)	Activity (ies)
Starting material (s)2		
Paracetamol	Analgesic	Synthesis, Purification, Packing, Labelling.

Use, whenever available. International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.
6. The requirements for good practices the manufacture and quality control of drugs referred to in the certificate are those included in Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials. Good manufacturing practices and inspection Volume 2, 1999. World Health Organization, Geneva and subsequent updates.

